MCR»·ëÄ£º¶à°ÐµãЭͬÔöЧ

MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖÐÌåÏÖ³öµÄ׿ԽÁÆЧ£¬£¬£¬£¬£¬£¬£¬£¬Ô´ÓÚÆä×÷ΪһÖÖЭͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄÆæÒìÉè¼Æ¡£¡£¡£¡£¡£¡£¡£¡£¸Ã·Ö×ÓʹÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ£¬£¬£¬£¬£¬£¬£¬£¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£¡£¡£¡£¡£¡£¡£¡£

ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄЭͬÔöЧЧӦ£¬£¬£¬£¬£¬£¬£¬£¬ÅäºÏ×÷ÓÃÓÚÌÇÄò²¡Éö²¡µÄ½¹µã²¡Àí»·½Ú£¬£¬£¬£¬£¬£¬£¬£¬×îÖÕµ¼ÖÂÂÑ°×Äò¼õÇá¡¢×ãϸ°û±£»£»£»£»£»£»£»£»¤¼°ÉöСÇòÂ˹ý¹¦Ð§¸ÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת£¬£¬£¬£¬£¬£¬£¬£¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤Õ½ÂÔÔÚÖØ´ó´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£¡£

¼¤»îMC1R£ºÃâÒßµ÷Àí¿¹Ñ×+ÒÖÖÆÏËά»¯Àú³Ì+Ö±½Ó±£»£»£»£»£»£»£»£»¤×ãϸ°û

MC1RÖ÷Òª±£´æÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£©¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬£¬£¬£¬£¬£¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯£¬£¬£¬£¬£¬£¬£¬£¬ïÔ̭һϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ±¬·¢^{2 3}£»£»£»£»£»£»£»£»Í¬Ê±Ôö½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å^{2 3}£¬£¬£¬£¬£¬£¬£¬£¬µ÷ÀíÃâÒßϸ°û£¬£¬£¬£¬£¬£¬£¬£¬¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬£¬£¬£¬£¬£¬Å¤×ªÉöÔà´ÙÑ×״̬¡£¡£¡£¡£¡£¡£¡£¡£

ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦Ð§ËðʧµÄ×îºóͨ·¡£¡£¡£¡£¡£¡£¡£¡£ÓÐÑо¿Åú×¢£¬£¬£¬£¬£¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶øïÔÌ­½ºÔ­ÂÑ°×µÈϸ°ûÍâ»ùÖʵĺϳɣ¬£¬£¬£¬£¬£¬£¬£¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄÀú³Ì⁴¡£¡£¡£¡£¡£¡£¡£¡£

×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ýÆÁÕϵÄÒªº¦Ï¸°û£¬£¬£¬£¬£¬£¬£¬£¬ÆäËðÉ˺ÍÍÑÂäÊÇÂÑ°×ÄòµÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£¡£¡£¡£Ò»Ð©Ñо¿Ö¸³ö£¬£¬£¬£¬£¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£©£¬£¬£¬£¬£¬£¬£¬£¬ÎȹÌÆäϸ°û¹Ç¼Ü£¬£¬£¬£¬£¬£¬£¬£¬ÒÖÖƵòÍö£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦Ð§µÄÍêÕûÐÔ£¬£¬£¬£¬£¬£¬£¬£¬ïÔÌ­ÂÑ°×Äò^{5 6}¡£¡£¡£¡£¡£¡£¡£¡£

ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÂþÑÜ⁵

¼¤»îMC4R£º¸ÄÉÆÒȵºËضԿ¹ºÍ´úл

MC4RÖ÷Òª±£´æÓÚÖÐÊàÉñ¾­ÏµÍ³£¬£¬£¬£¬£¬£¬£¬£¬¼ÓÈëµ÷ÀíÄÜÁ¿Æ½ºâºÍʳÓû¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC4R£¬£¬£¬£¬£¬£¬£¬£¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл£¬£¬£¬£¬£¬£¬£¬£¬ÓÐÀûÓÚ´ÓȪԴÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£¡£¡£¡£¡£¡£¡£¡£

MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ

Õ¹ÍûδÀ´£¬£¬£¬£¬£¬£¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆΪ»ùʯ£¬£¬£¬£¬£¬£¬£¬£¬ÒÀ¸½Æä×÷ÓûúÖƵĽ¹µãÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬Æð¾¢ÍØÕ¹ÖÐÊàÉñ¾­ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦ÖØ´óµÄÐÂ˳Ӧ֢ÁìÓò¡£¡£¡£¡£¡£¡£¡£¡£

Êг¡Ô¶¾°ÓëÕ½ÂԽṹ

È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔöÌí½×¶Î£¬£¬£¬£¬£¬£¬£¬£¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õß»áÉú³¤ÎªÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬£¬£¬»¼Õß»ùÊýÖش󡣡£¡£¡£¡£¡£¡£¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬£¬£¬Ô¤¼Æ2030Ä꽫Áè¼Ý300ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬£¬£¬Ä긴ºÏÔöÌíÂÊ´ï12.5%⁷¡£¡£¡£¡£¡£¡£¡£¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò£¬£¬£¬£¬£¬£¬£¬£¬ÕïÁÆÂʵÄÒ»Á¬ÌáÉýʹÆä³ÉΪ×î¾ßÔöÌí»îÁ¦µÄÊг¡Ö®Ò»¡£¡£¡£¡£¡£¡£¡£¡£

Ö»¹ÜÏÖÓбê×¼ÁÆ·¨Ò»Ö±½ø»¯£¬£¬£¬£¬£¬£¬£¬£¬µ«ÉÐÎÞÄܹ»ÄæתÏËά»¯Àú³ÌµÄÌØÒìÐÔÒ©Îï¡£¡£¡£¡£¡£¡£¡£¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷ÀíÈý´ó½¹µã»·½Úͬʱ½éÈ룬£¬£¬£¬£¬£¬£¬£¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÒ컥²¹£¬£¬£¬£¬£¬£¬£¬£¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸ÆæÒì²î±ð»¯ÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£¡£

ÏÖÔÚ£¬£¬£¬£¬£¬£¬£¬£¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø£¬£¬£¬£¬£¬£¬£¬£¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Ó붾ÀíѧÑо¿£¬£¬£¬£¬£¬£¬£¬£¬Ïà¹Ø½¹µã»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ£¬£¬£¬£¬£¬£¬£¬£¬¹¹½¨Á˼áʵµÄÊÖÒÕ±ÚÀÝ¡£¡£¡£¡£¡£¡£¡£¡£ÔÚ´ËרÀû¼Ó³ÖÏ£¬£¬£¬£¬£¬£¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«È«Á¦¼ÓËÙÕâÒ»²î±ð»¯¶àëÄÐÂÒ©µÄÑз¢Àú³Ì£¬£¬£¬£¬£¬£¬£¬£¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´²£¬£¬£¬£¬£¬£¬£¬£¬Ô츣ȫÇò»¼Õߣ¬£¬£¬£¬£¬£¬£¬£¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂԸߵØ¡£¡£¡£¡£¡£¡£¡£¡£

×ÊÁÏȪԴ

1.Öйú¹«ÖÚ¿µ½¡Íø£¨2014£©£¬£¬£¬£¬£¬£¬£¬£¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html

2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683

3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815

4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx

5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236

6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf

7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÔ¶¾°ÊÓ²ìÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm